Search This Blog

Wednesday, August 29, 2018

Evofem advancing Amphora gel for prevention of certain STDs in women


Thinly traded nano cap Evofem Biosciences (EVFM +14.5%) is up on a 4x surge in volume, albeit on turnover of only 259K shares. The stock has rallied over 60% since touching $1.83 on August 8.
This morning, it announced new CDC data that showed increasing rates of sexually transmitted diseases (STDs) in the U.S. Specifically, 2.3M cases were reported, up almost 10% in a year.
The company’s lead candidate is Amphora, a vaginal gel in Phase 3 development as an on-demand hormone-free contraceptive (topline data expected by year-end) and in Phase 2b development for the prevention of STDs chlamydia and gonorrhea.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.